Literature DB >> 22771028

High frequency of discordance between antimüllerian hormone and follicle-stimulating hormone levels in serum from estradiol-confirmed days 2 to 4 of the menstrual cycle from 5,354 women in U.S. fertility centers.

Benjamin Leader1, Aparna Hegde, Quentin Baca, Kimberly Stone, Benjamin Lannon, David B Seifer, Frank Broekmans, Valerie L Baker.   

Abstract

OBJECTIVE: To determine the frequency of clinical discordance between antimüllerian hormone (AMH, ng/mL) and follicle-stimulating hormone (FSH, IU/L) by use of cut points defined by response to controlled ovarian stimulation in the same serum samples drawn on estradiol-confirmed, menstrual cycle days 2 to 4.
DESIGN: Retrospective analysis.
SETTING: Fertility centers in 30 U.S. states and a single reference laboratory with uniform testing protocols. PATIENT(S): 5,354 women, 20 to 45 years of age. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Frequency of discordance between serum AMH and FSH values. RESULT(S): Of the 5,354 women tested, 1 in 5 had discordant AMH and FSH values defined as AMH <0.8 (concerning) with FSH <10 (reassuring) or AMH ≥ 0.8 (reassuring) with FSH ≥ 10 (concerning). Of the women with reassuring FSH values (n = 4,469), the concerning AMH values were found in 1 in 5 women in a highly age-dependent fashion, ranging from 1 in 11 women under 35 years of age to 1 in 3 women above 40 years of age. On the other hand, of the women with reassuring AMH values (n = 3,742), 1 in 18 had concerning FSH values, a frequency that did not vary in a statistically significant fashion by age. CONCLUSION(S): Clinical discordance in serum AMH and FSH values was frequent and age dependent using common clinical cut points, a large patient population, one reference laboratory, and uniform testing methodology. This conclusion is generalizable to women undergoing fertility evaluation, although AMH testing has not been standardized among laboratories, and the cut points presented are specific to the laboratory in this study.
Copyright © 2012. Published by Elsevier Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22771028     DOI: 10.1016/j.fertnstert.2012.06.006

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  10 in total

1.  AMH in women with diminished ovarian reserve: potential differences by FMR1 CGG repeat level.

Authors:  Lisa M Pastore; Timothy L McMurry; Christopher D Williams; Valerie L Baker; Steven L Young
Journal:  J Assist Reprod Genet       Date:  2014-06-18       Impact factor: 3.412

Review 2.  Anti-Müllerian hormone as a marker of ovarian reserve: What have we learned, and what should we know?

Authors:  Akira Iwase; Tomoko Nakamura; Satoko Osuka; Sachiko Takikawa; Maki Goto; Fumitaka Kikkawa
Journal:  Reprod Med Biol       Date:  2015-11-23

3.  Investigation of the Predictive Factors of Diminished Ovarian Reserve in Women Aged Less Than 40 Years and Undergoing ICSI Cycle.

Authors:  Mohammed M Laqqan; Maged M Yassin
Journal:  Reprod Sci       Date:  2022-08-24       Impact factor: 2.924

Review 4.  Reproductive ovarian testing and the alphabet soup of diagnoses: DOR, POI, POF, POR, and FOR.

Authors:  Lisa M Pastore; Mindy S Christianson; James Stelling; William G Kearns; James H Segars
Journal:  J Assist Reprod Genet       Date:  2017-10-02       Impact factor: 3.412

5.  Discrepancies between Antimullerian Hormone and Follicle Stimulating Hormone in Assisted Reproduction.

Authors:  Munawar Hussain; David Cahill; Valentine Akande; Uma Gordon
Journal:  Obstet Gynecol Int       Date:  2013-12-18

6.  Ovarian response and cumulative live birth rate of women undergoing in-vitro fertilisation who had discordant anti-Mullerian hormone and antral follicle count measurements: a retrospective study.

Authors:  Hang Wun Raymond Li; Vivian Chi Yan Lee; Estella Yee Lan Lau; William Shu Biu Yeung; Pak Chung Ho; Ernest Hung Yu Ng
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

7.  Nomogram to predict the number of oocytes retrieved in controlled ovarian stimulation.

Authors:  Kyoung Yong Moon; Hoon Kim; Joong Yeup Lee; Jung Ryeol Lee; Byung Chul Jee; Chang Suk Suh; Ki Chul Kim; Won Don Lee; Jin Ho Lim; Seok Hyun Kim
Journal:  Clin Exp Reprod Med       Date:  2016-06-23

Review 8.  Fertility with early reduction of ovarian reserve: the last straw that breaks the Camel's back.

Authors:  Sabahat Rasool; Duru Shah
Journal:  Fertil Res Pract       Date:  2017-10-11

Review 9.  Maximizing the clinical utility of antimüllerian hormone testing in women's health.

Authors:  Benjamin Leader; Valerie L Baker
Journal:  Curr Opin Obstet Gynecol       Date:  2014-08       Impact factor: 1.927

10.  Discordant anti-müllerian hormone (AMH) and follicle stimulating hormone (FSH) among women undergoing in vitro fertilization (IVF): which one is the better predictor for live birth?

Authors:  Shunping Wang; Yi Zhang; Virginia Mensah; Warren J Huber; Yen-Tsung Huang; Ruben Alvero
Journal:  J Ovarian Res       Date:  2018-07-16       Impact factor: 4.234

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.